Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - valsartan, quantity: 320 mg; hydrochlorothiazide, quantity: 25 mg; amlodipine besilate, quantity: 13.87 mg (equivalent: amlodipine, qty 10 mg) - tablet, film coated - excipient ingredients: magnesium stearate; colloidal anhydrous silica; crospovidone; microcrystalline cellulose; hypromellose; purified talc; iron oxide yellow; macrogol 4000 - amlodipine/valsartan/hct novartis is indicated only as substitution therapy for the treatment of hypertension in patients whose blood pressure is already adequately controlled on the triple combination of amlodipine, valsartan and hydrochlorothiazide taken either as three single component formulations or as dual-component formulation with a single component formulation, all components at the same dose level. treatment should not be initiated with these fixed-dose combinations (see dosage and administration).

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - valsartan, quantity: 160 mg; amlodipine besilate, quantity: 13.87 mg (equivalent: amlodipine, qty 10 mg); hydrochlorothiazide, quantity: 12.5 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; colloidal anhydrous silica; crospovidone; magnesium stearate; hypromellose; purified talc; iron oxide red; macrogol 4000; iron oxide yellow; titanium dioxide - amlodipine/valsartan/hct novartis is indicated only as substitution therapy for the treatment of hypertension in patients whose blood pressure is already adequately controlled on the triple combination of amlodipine, valsartan and hydrochlorothiazide taken either as three single component formulations or as dual-component formulation with a single component formulation, all components at the same dose level. treatment should not be initiated with these fixed-dose combinations (see dosage and administration).

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - amlodipine besilate, quantity: 13.87 mg (equivalent: amlodipine, qty 10 mg) - tablet, uncoated - excipient ingredients: calcium hydrogen phosphate; microcrystalline cellulose; sodium starch glycollate; magnesium stearate - hypertension: first line treatment of hypertension. it can be used as the sole agent to control blood pressure in the majority of patients. patients not adequately controlled on a single antihypertensive agent may benefit from the addition of amlodipine besylate, which has been used in combination with a thiazide diuretic, beta-adrenoreceptor blocking agent, or an angiotensin converting enzyme inhibitor. angina: first line treatment of chronic stable angina. amlodipine besylate may be used alone, as monotherapy, or in combination with other antianginal drugs.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - amlodipine besilate, quantity: 6.94 mg (equivalent: amlodipine, qty 5 mg); perindopril arginine, quantity: 5 mg - tablet - excipient ingredients: microcrystalline cellulose; colloidal anhydrous silica; magnesium stearate; croscarmellose sodium - perindopril arginine and amlodipine combination tablet is indicated as substitution therapy for the treatment of hypertension and/or stable coronary heart disease in patients already controlled with separate doses of perindopril and amlodipine, given concurrently at the same dose level. treatment should not be initiated with this combination.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - amlodipine besilate, quantity: 6.94 mg; telmisartan, quantity: 40 mg - tablet, uncoated - excipient ingredients: silicon dioxide; iron oxide yellow; croscarmellose sodium; mannitol; meglumine; brilliant blue fcf aluminium lake; povidone; iron oxide black; microcrystalline cellulose; isomalt; calcium hydrogen phosphate; sodium hydroxide; magnesium stearate - treatment of hypertension. treatment should not be initiated with this fixed-dose combination.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - amlodipine besilate, quantity: 6.94 mg; telmisartan, quantity: 80 mg - tablet, uncoated - excipient ingredients: croscarmellose sodium; calcium hydrogen phosphate; microcrystalline cellulose; mannitol; magnesium stearate; iron oxide yellow; isomalt; brilliant blue fcf aluminium lake; silicon dioxide; sodium hydroxide; povidone; meglumine; iron oxide black - treatment of hypertension. treatment should not be initiated with this fixed-dose combination.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - amlodipine besilate, quantity: 6.94 mg (equivalent: amlodipine, qty 5 mg); valsartan, quantity: 320 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; magnesium stearate; iron oxide yellow; crospovidone; sodium starch glycollate; colloidal anhydrous silica; hypromellose; purified talc; iron oxide red; macrogol 4000 - exforge is indicated for the treatment of hypertension. treatment should not be initiated with this fixed dose combination.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - amlodipine besilate, quantity: 6.94 mg (equivalent: amlodipine, qty 5 mg); valsartan, quantity: 160 mg - tablet, film coated - excipient ingredients: magnesium stearate; crospovidone; microcrystalline cellulose; colloidal anhydrous silica; hypromellose; purified talc; iron oxide yellow; macrogol 4000; titanium dioxide - treatment of hypertension. treatment should not be initiated with this fixed dose combination.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - amlodipine besilate, quantity: 13.9 mg; hydrochlorothiazide, quantity: 12.5 mg; olmesartan medoxomil, quantity: 40 mg - tablet, film coated - excipient ingredients: lactose monohydrate; magnesium stearate; povidone; pregelatinised maize starch; silicified microcrystalline cellulose; isopropyl alcohol; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350 - apo-olmesartan/amlodipine/hctz 40/10/12.5 mg is indicated for the treatment of hypertension, either as replacement for olmesartan medoxomil, amlodipine and hydrochlorothiazide being already taken as separate tablets or as add-on therapy where a patient's blood pressure is not controlled on a dual combination. this fixed dose combination is not indicated for initial therapy.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - amlodipine besilate, quantity: 13.9 mg; hydrochlorothiazide, quantity: 25 mg; olmesartan medoxomil, quantity: 40 mg - tablet, film coated - excipient ingredients: isopropyl alcohol; silicified microcrystalline cellulose; povidone; lactose monohydrate; pregelatinised maize starch; magnesium stearate; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350 - apo-olmesartan/amlodipine/hctz 40/10/25 mg is indicated for the treatment of hypertension, either as replacement for olmesartan medoxomil, amlodipine and hydrochlorothiazide being already taken as separate tablets or as add-on therapy where a patient's blood pressure is not controlled on a dual combination. this fixed dose combination is not indicated for initial therapy.